Investor Overview
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.
Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is at the stage of Phase I clinical development.
Our Business Model
- Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization. The preferred stage of development for out-licensing is early clinical Proof of Concept.
- Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both proteins and mRNA – needed to generate a pipeline of first-in-class drug candidates.
- Our approach to drug discovery is based on bold target selection, both proteins and mRNA, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
- Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.
Investor's calendar
| DATE | EVENT |
|---|---|
| March 30, 2023 | Publication of the Company's Annual Reports for the year 2022 |
| April 28, 2023 | Publication of the Company’s 1st quarter 2023 report |
| May 3-4, 2023 | LSX World Congress, London |
| May 14-16, 2023 | 23rd BioEquity Europe, Dublin |
| June 5-8, 2023 | BIO International Convention, Boston |
| September 29, 2023 | Publication of the Company’s half year 2023 report |
| October 31, 2023 | Publication of the Company’s 3rd quarter 2023 report |
Stock Quotes
Shareholding Structure
Shareholders
| NUMBER OF SHARES | NOMINAL VALUE OF SHARES | SHARE IN THE SHARE CAPITAL | SHARE IN THE NUMBER OF VOTES | |
|---|---|---|---|---|
| BLACK FOREST SICAV - SIF societe anonyme | 4 999 310 | 49 993,00 | 29,7% | 29,7% |
| Marcin Szumowski together with Szumowski Investments Sp. z o.o. | 1 127 163 | 11 271,63 | 6,7% | 6,7% |
| Nationale-Nederlanden Universal Pension Society SA | 1 445 819 | 14 458,19 | 8,6% | 8,6% |
| Others | 9 263 708 | 92 637,08 | 55,0% | 55,0% |
| TOTAL | 16 836 000 | 168 360,00 | 100,00% | 100,00% |
* Members of the Management Board, Supervisory Board and shareholders of the Company do not hold any shares of BLACK FOREST SICAV-SIF societe anonyme. The indirect owner of the shares is Michał Andrzej Sołowow.
Share in capital and number of votes
Financial Information
Financial Summary
ON the WSE FROM
April 19, 2018
MARKET / QUOTATION SEGMENT
WSE / Parallel
SECTOR (WSE)
Biotechnology
INDEX AFFILIATION
WIG-Poland, WIG
WSE TICKER
MOC
ISIN
PLONCTH00011
NUMBER OF SHARES ISSUED
16 836 000
Analyst Coverage
2023-09-28
In preparation for Molecure’s forthcoming clinical and preclinical R&D activities, management has secured (secondary) financing with a gross value of around PLN50m (c $12m). The Phase II trial for OATD-01, which was recently FDA approved for clinical studies as an Investigational New Drug (IND), is top priority. The company will seek EMA approval in the coming weeks so that it can proceed with Phase II studies in both the US and EU in parallel. It will also employ the proceeds to support the ongoing Phase I trial of OATD-02 in patients with solid tumours (updates expected in H223), and intensify efforts on its early-stage programmes, specifically focused on small molecule drug candidates designed to modulate underexplored protein targets and the function of mRNA. We view the capital raise as a positive development in light of the challenging macro environment.
Research link
Go to Analyzes & Recommendations on ipopema.pl
Contact
Contact with the media and individual investors
Michał Wierzchowski
CC GROUP
+48 531 613 067 +48 22 440 1 440michal.wierzchowski@ccgroup.pl
Contact with institutional investors and sell-side analysts
Katarzyna Mucha
CC GROUP
+48 697 613 712 +48 22 440 1 440katarzyna.mucha@ccgroup.pl